Tehran University of Medical Sciences Iranian Journal of Public Health 2251-6085 54 2 2025 02 08 333 345 Narges Fereydouni 1. Department of Tissue Engineering, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran 2. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran 3. Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran Mohammad Ebrahim ‎ Astaneh 1. Department of Tissue Engineering, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran 2. Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran 3. Department of Anatomical Sciences, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran Morteza Seifalah-Zade‎ 1. Department of Tissue Engineering, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran 2. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran 3. Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran Alireza Hashemzadeh Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2024 04 08 2024 10 06 Background: This review represents the first comprehensive compilation of data on Iranian commercial, service, and research entities in the field of tissue engineering up to 2024. Methods: Through an extensive search of official websites, 56 companies were identified: 29 commercial enterprises, 17 service providers, and 10 research institutions. The majority (64%) of these companies are headquartered in Tehran, with many established post-2004. Results: Biomaterials account for half of the product portfolio, with 38% of ongoing research focused on this area. Although cell-based products currently make up only 12% of offerings, they are the subject of 38% of current research, indicating significant potential for future growth. Conclusion: This study provides a detailed overview of the development and future prospects of Iran's tissue engineering sector. The key conclusion emphasizes the need for an expanded focus on cell-based therapies and the establishment of stronger regulatory frameworks to facilitate the commercialization of innovative products. The review identifies key research gaps and proposes directions for future study, utilizing a descriptive methodology with in-depth data analysis and theoretical discussion. https://ijph.tums.ac.ir/index.php/ijph/article/view/35169 https://ijph.tums.ac.ir/index.php/ijph/article/download/35169/8468